Use of depot antipsychotic medications for medication nonadherence in schizophrenia

Schizophrenia Bulletin

Volumn 34, Issue 5, 2008, Pages 995-1001

  West, Joyce C ^a   Marcus, Steven C ^b   Wilk, Joshua ^a   Countis, Lisa M ^a   Regier, Darrel A ^a   Olfson, Mark ^c  

^a AMERICAN PSYCHIATRIC ASSOCIATION   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Antipsychotics; Depot; Nonadherence

Indexed keywords

FLUPHENAZINE DECANOATE; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; FEMALE; HEALTH INSURANCE; HOSPITAL ADMISSION; HUMAN; INJECTION; INTELLIGENCE; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH SERVICE; OUTPATIENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHIATRIST; SCHIZOPHRENIA; TREATMENT REFUSAL;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PATIENT COMPLIANCE; SCHIZOPHRENIA;

EID: 54149085188     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbm137     Document Type: Article

References (34)

1. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull. 1997;23:637-651.
2. West JC, Wilk JE, Olfson M, et al. Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice. Psychiatr Serv. 2005;283-291.
3. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999; 56:241-247.
4. Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv. 2001;52: 805-811.
5. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk or rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004; 55:886-891.
6. Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The schizophrenia patient outcomes research team (PORT): update treatment recommendations 2003. Schizophr Bull. 2004;30: 193-217.
7. Valenstein M, Copeland LA, Owne R, Blow FC, Visnic S. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. J Clin Psychiatry. 2001;62:545-551.
8. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley & Sons, Inc; 1989.
9. Berwick DM. Disseminating innovations in health care. JAMA. 2003;289:1969-1975.
10. Ferris LE, De Siato C, Sandercock J, Williams JI, Shulman KI. Working Group: a descriptive analysis of two mobile crisis programs for clients with severe mental illness. Can J Public Health. 2003;94:233-237.
11. Glick ID, Pham D, Davis JM. Concomitant medications may not improve outcome of antipsychotic monotherapy for stabilized patients with nonacute schizophrenia. J Clin Psychiatry. 2006;67:1261-1265.
12. Magliano L, Fiorillo A, Guarneri M, et al. The National Mental Health Project Working Group: prescription of psychotropic drugs to patients with schizophrenia: an Italian national survey. Eur J Clin Pharmacol. 2004;60:513-522.
13. Nose M, Barbui C, Tansella M. How often do patients with psychosis fail to adhere to treatment programmes? A systematic review. Psychol Med. 2003;33:1149-1160.
14. Wang EC, Choe MC, Meara JG, Koempel JA. Inequality of access to surgical specialty health care: why children with government-funded insurance have less access than those with private insurance in Southern California. Pediatrics. 2004;114:584-590.
15. Olfson M, Marcus S, Sackeim HA, Thompson J, Pincus HA. Use of ECT for the inpatient treatment of recurrent major depression. Am J Psychiatry. 1998;155:22-29.
16. Seldon TM, Hudson JL. Access to care and utilization among children: estimating the effects of public and private coverage. Med Care. 2006;44(suppl 5):I19-26.
17. Rice T, Laverreda SA, Ponce NA, Brown RE. The impact of private and public health insurance on medication use for adults with chronic diseases. Med Care Res Rev. 2005;62: 231-249.
18. Olfson M, Marcus SC, Wilk J, West JC. Awareness of illness and nonadherence to antipsychotic medications among persons with schizophrenia. Psychiatr Serv. 2006;57:205-211.
19. Patel MX, Nikolaou V, David AS. Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychol Med. 2003;33:83-89.
20. Cooper-Patrick L, Gallo JJ, Gonzales JJ, et al. Race, gender, and partnership in the patient-physician relationship. JAMA. 1999;282:583-589.
21. Citrome L, Levine J, Allingham B. Utilization of depot neuroleptic medication in psychiatric inpatients. Psychopharmacol Bull. 1996;32:321-326.
22. Mark TL, Palmer LA, Russo PA, Vasey L. Examination of treatment pattern differences by race. Ment Health Serv Res. 2003;5:241-250.
23. Arnold LM, Strakowski SM, Schwiers ML, et al. Sex, ethnicity, and antipsychotic medication use inpatients with psychosis. Schizophr Res. 2004;66:169-175.
24. Kreyenbuhl J, Zito JM, Buchanan RW, Soeken KL, Lehman AF. Racial disparity in the pharmacological management of schizophrenia. Schizophr Bull. 2003;29:183-193.
25. Price N, Glazer W, Margenstern H. Demographic predictors of the use of injectable versus oral antipsychotic medications in outpatients. Am J Psychiatry. 1985;142:1491-1492.
26. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry. 2002;63:1121-1128.
27. Byerly M, Fisher R, Whatley K, et al. A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychol Res. 2005; 133:129-133.
28. Walburn J, Gray R, Gournay K, Qurashi S, David AS. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry. 2001;179:300-307.
29. Niaz OS, Haddad PM. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatr Scand. 2007;116:36-46.
30. Parellada E, Adrezina R, Milanova V, et al. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. J Psychopharmacol. 2005;19(suppl 5):5-14.
31. Moller JH, Llorca PM, Sacchetti E, Martin SDD, Medori R, Parellada E. StoRMi Study Group: Efficacy and safety of direct transition to risperidone long-acting injectable inpatients treated with various antipsychotic therapies. Int Clin Psychopharmacol. 2005;20:121-130.
32. Taylor DM, Young CL, Mace S, Patel MX. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. J Clin Psychiatry. 2004;65:1076-1083.
33. Taylor DM, Young C, Patel MX. Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome. Int J Neuropsychopharmacol. 2006;9:685-694.
34. Patel MX, Young C, Samele C, Taylor DM, David AS. Prognostic indicators for early discontinuation of risperidone long-acting injection. Int Clin Psychopharmacol. 2004;19: 233-239.